Nuvectra Corporation (NASDAQ:NVTR) has earned a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $13.00.

Several equities research analysts recently commented on NVTR shares. B. Riley reiterated a “buy” rating and issued a $12.00 price objective on shares of Nuvectra Corporation in a report on Wednesday, May 10th. Zacks Investment Research cut Nuvectra Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, May 13th. ValuEngine raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. TheStreet raised Nuvectra Corporation from a “d” rating to a “c-” rating in a research report on Monday, June 19th. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $14.00 target price on shares of Nuvectra Corporation in a research report on Thursday, July 6th.

ILLEGAL ACTIVITY WARNING: “Nuvectra Corporation (NASDAQ:NVTR) Given Average Recommendation of “Hold” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/12/nuvectra-corporation-nasdaqnvtr-given-average-recommendation-of-hold-by-analysts.html.

In other news, CEO Scott F. Drees bought 2,605 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $9.92 per share, with a total value of $25,841.60. Following the completion of the transaction, the chief executive officer now owns 90,041 shares of the company’s stock, valued at approximately $893,206.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Scott F. Drees bought 7,395 shares of the company’s stock in a transaction on Tuesday, May 30th. The stock was purchased at an average cost of $10.41 per share, for a total transaction of $76,981.95. Following the completion of the transaction, the chief executive officer now directly owns 99,136 shares of the company’s stock, valued at approximately $1,032,005.76. The disclosure for this purchase can be found here. Insiders acquired 20,000 shares of company stock worth $220,024 over the last three months.

A number of hedge funds and other institutional investors have recently made changes to their positions in NVTR. Renaissance Technologies LLC boosted its position in shares of Nuvectra Corporation by 77.7% in the fourth quarter. Renaissance Technologies LLC now owns 86,200 shares of the company’s stock valued at $434,000 after buying an additional 37,700 shares during the last quarter. Granite Investment Partners LLC purchased a new position in shares of Nuvectra Corporation during the first quarter valued at about $702,000. Essex Investment Management Co. LLC boosted its position in shares of Nuvectra Corporation by 17.7% in the first quarter. Essex Investment Management Co. LLC now owns 142,589 shares of the company’s stock valued at $974,000 after buying an additional 21,469 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Nuvectra Corporation by 0.7% in the first quarter. Wells Fargo & Company MN now owns 112,997 shares of the company’s stock valued at $772,000 after buying an additional 751 shares during the last quarter. Finally, Hodges Capital Management Inc. boosted its position in shares of Nuvectra Corporation by 7.8% in the first quarter. Hodges Capital Management Inc. now owns 192,101 shares of the company’s stock valued at $1,312,000 after buying an additional 13,840 shares during the last quarter. 59.91% of the stock is currently owned by institutional investors and hedge funds.

Nuvectra Corporation (NASDAQ NVTR) opened at 11.65 on Friday. The company’s market cap is $122.20 million. Nuvectra Corporation has a 12-month low of $4.63 and a 12-month high of $15.00. The stock’s 50 day moving average is $12.34 and its 200 day moving average is $9.23.

Nuvectra Corporation (NASDAQ:NVTR) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.07. Nuvectra Corporation had a negative return on equity of 56.68% and a negative net margin of 232.31%. The company had revenue of $7.20 million during the quarter, compared to the consensus estimate of $5.96 million. During the same period last year, the company earned ($0.85) EPS. Nuvectra Corporation’s revenue for the quarter was up 188.0% on a year-over-year basis. On average, equities analysts forecast that Nuvectra Corporation will post ($4.77) earnings per share for the current year.

About Nuvectra Corporation

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.